Form Type:  SC 13G/A
Filing Date:  2/11/2019 
CIK:  0000704159 
Address:  222 THIRD STREET
SUITE 2241
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  (617) 830-3031 
Fiscal Year:  12/31 
Description of Business
VBI is a pharmaceutical company developing novel technologies that seek to expand vaccine protection in large, underserved markets. We have developed an eVLP vaccine platform that allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. Using this proprietary technology platform, we have undertaken specific projects related to human cytomegalovirus ("CMV") and other antigens. In 2015, the Company prepared several batches of vaccine for a toxicology trial, in compliance with the Good Manufacturing Practices ("GMP") enforced by the US Food and Drug Administration ("FDA"), for a Phase I clinical trial and for other regulatory purposes. In April 2015, we began the toxicology trial for our human CMV vaccine.
Register and access this filing in: